-
Swede goes on trial for pressuring wife to sell sex
-
US inflation surges 3.3% as Iran war impact bites
-
Vance warns Iran not to 'play' US at talks in Pakistan
-
Fernandez remains out despite apology: Chelsea boss Rosenior
-
Dortmund defender Schlotterbeck extends contract until 2031
-
De Zerbi vows to save troubled Spurs from relegation
-
Antwerp port reopens to North Sea shipping after oil spill
-
Stocks mixed, oil steadies on guarded optimism for Iran ceasefire
-
Sinner eases into Monte Carlo semi-finals
-
France's Macron talks war, peace and basketball with Pope Leo
-
Fernandez apologised over comments about his future: Chelsea's Rosenior
-
Coach Spalletti signs new Juve deal until 2028
-
AI chatbots offer children harm as if it were help, says activist
-
'Grumpy' Guardiola wants Silva to stay at Man City for life
-
Zverev beats Fonseca to reach Monte Carlo semi-finals
-
Scheffler, Rose to chase McIlroy with early Masters starts
-
Celine Dion's Paris concerts promise to spin the money on and on
-
Stocks climb, oil steadies on guarded optimism over Iran war ceasefire
-
Irish govt to meet farmers, hauliers over fuel cost fears
-
Injured Bayern starlet Karl to miss Real return leg
-
US-Iran talks in Pakistan uncertain as sides trade accusations
-
Oil spill snarls shipping traffic in Antwerp port
-
Giving birth in a shelter in Israel
-
Five things to know about the planned Iran-US talks in Islamabad
-
Slot feels 'complete support' from Liverpool chiefs despite slump
-
Kyiv books tentative diplomatic coup with Iran war forays
-
Teenager shines as Britain seize control of BJK Cup tie with Australia
-
Chinese, Taiwanese will unite, Xi tells Taiwan opposition leader
-
Sleepy seal diverts traffic in Australian seaside town
-
Artemis astronauts to shed light on space health risks
-
Pakistan prepares to host US-Iran talks, as Lebanon fighting continues
-
Vaccine gaps fuel Bangladesh's deadly measles crisis
-
Fish furore fuels fierce election in India's West Bengal
-
Coachella kicks off with headliners Sabrina Carpenter, Bieber and Karol G
-
Myanmar junta chief sworn in as president
-
Exiled cartoonists give voice to Iran's silenced millions
-
In Pakistan's mediation to end Mideast war, China may hold the key
-
Knicks stay in hunt with late win over rival Celtics
-
'Sartorial diplomacy' on show in expo of late UK queen's fashion
-
Former Japan and AC Milan star Honda laces up boots again at 39
-
Stocks rally on optimism over Iran war ceasefire, oil extends gains
-
Lego-style memes troll Trump after fragile US-Iran truce
-
Chinese slimmers trade lost fat for beef
-
Jackson biopic shows franchise thriving despite abuse claims
-
New Jersey city spurns data center as defiance spreads
-
US box office looking good as cinema owners gather: industry chief
-
Firm Masters greens make life hard on golf's finest
-
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Designed for the Desk, Built for the Day: The Epomaker TH108 V2 Pro
-
Releaf Crosses 25,000 Patients With Record Revenue
Avant Technologies Reaches Global Development and Licensing Deal with Partner, Ainnova Tech, Ahead of FDA Meetings
LAS VEGAS, NV / ACCESS Newswire / February 25, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the companies have agreed to expand the territory for Ai-nova Acquisition Corp. (AAC), the joint venture formed by both companies. In an addendum to the December 2024 Joint Venture Agreement between Avant and Ainnova, AAC's territory now includes a global license to develop and market Ainnova's "technology portfolio."
The partnership was formed to advance and commercialize Ainnova's portfolio, including its Vision AI platform and its proprietary versatile retinal camera technology. Vision AI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases, as well as diseases unrelated to the retina like cardiovascular disease, prediabetes and type 2 diabetes, fatty liver diseases, and chronic kidney disease with high accuracy and speed using retinal scans. Meanwhile, Ainnova's next-generation versatile retinal cameras are seamlessly integrated with Vision AI for precise retinal scans.
Under the amended agreement, Ainnova's Vision AI software, combined with its retinal cameras, will offer AAC SaaS + retinal camera commercialization opportunities with opticians and eye care centers worldwide.
Avant has broadened its territory, through the joint venture, ahead of Ainnova's meetings with the U.S. Food and Drug Administration (FDA) to prepare for a planned FDA clinical trial with its Vision AI platform. Ainnova will begin by requesting a pre-submission meeting with the FDA for guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy, which will culminate with an FDA 510(k) submission to obtain clearance from the FDA to market its technology.
For Avant, the presubmission meeting will help define a precise budget for the strategic partnership's entire FDA process, and the success of Ainnova's interactions with the FDA are paramount to AAC marketing the technology portfolio in the United States.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
[email protected]
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
E.Hall--AT